SCHEMBL4666064

SCHEMBL4666064

CN(C)CCCn1cnc2cc(-c3cc(Nc4ccc(N(OC=O)S(=O)(=O)c5ccccc5F)cc4)ncn3)ccc21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.37
CYP2C9 P11712 3/20 0.37
CLK4 Q9HAZ1 3/20 0.37
MAPK1 P28482 2/20 0.37
USP2 O75604 2/20 0.37
CYP3A4 P08684 2/20 0.37
CYP2D6 P10635 2/20 0.37
CYP2C19 P33261 2/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
TP53 P04637 1/20 0.37
GLA P06280 1/20 0.37
ALOX15 P16050 1/20 0.37
KMT2A Q03164 1/20 0.37
HSD17B10 Q99714 1/20 0.37
NR1I2 O75469 2/20 0.36
TGFBR1 P36897 1/20 0.36
KDM4E B2RXH2 1/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4663971 0.93 MAPK1 (0.37) CYP1A2CYP2C9CLK4MAPK1USP2
SCHEMBL4664328 0.92 MAPK1 (0.36) CYP1A2CYP2C9CLK4MAPK1USP2
SCHEMBL4665682 0.86 ABL1 (0.38) CYP1A2CYP2C9CLK4MAPK1USP2
Formic Acid SCHEMBL4666063 0.85 NR1I2 (0.46) CYP1A2CYP2C9CLK4MAPK1USP2
SCHEMBL4663922 0.84 BPTF (0.39) CYP1A2CYP2C9CLK4MAPK1USP2
SCHEMBL4663840 0.83 EGFR (0.40) CYP1A2CYP2C9CLK4MAPK1USP2
SCHEMBL4664284 0.82 HTR6 (0.38) CYP1A2CYP2C9CLK4MAPK1USP2
SCHEMBL4664243 0.81 HTR6 (0.42) CYP1A2CYP2C9CLK4MAPK1USP2
Formic Acid SCHEMBL4663967 0.81 NR1I2 (0.40) CYP1A2CYP2C9CLK4MAPK1USP2
SCHEMBL4665759 0.79 ABL1 (0.36) CYP1A2CYP2C9CLK4MAPK1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 CYP1A2 1215/4885CYP2C9 1047/4885CLK4 586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.